- Home
- ZTEK vs CRDF Comparison
ZTEK vs CRDF Comparison
Compare ZTEK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- CRDF
- Stock Information
- Founded
- ZTEK 2008
- CRDF 1999
- Country
- ZTEK Canada
- CRDF United States
- Employees
- ZTEK N/A
- CRDF N/A
- Industry
- ZTEK Major Chemicals
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZTEK Industrials
- CRDF Health Care
- Exchange
- ZTEK Nasdaq
- CRDF Nasdaq
- Market Cap
- ZTEK 165.9M
- CRDF 169.6M
- IPO Year
- ZTEK N/A
- CRDF N/A
- Fundamental
- Price
- ZTEK $1.33
- CRDF $3.18
- Analyst Decision
- ZTEK
- CRDF Strong Buy
- Analyst Count
- ZTEK 0
- CRDF 4
- Target Price
- ZTEK N/A
- CRDF $12.25
- AVG Volume (30 Days)
- ZTEK 29.1K
- CRDF 1.2M
- Earning Date
- ZTEK 08-13-2025
- CRDF 08-07-2025
- Dividend Yield
- ZTEK N/A
- CRDF N/A
- EPS Growth
- ZTEK N/A
- CRDF N/A
- EPS
- ZTEK N/A
- CRDF N/A
- Revenue
- ZTEK $44,936.00
- CRDF $587,000.00
- Revenue This Year
- ZTEK N/A
- CRDF N/A
- Revenue Next Year
- ZTEK N/A
- CRDF N/A
- P/E Ratio
- ZTEK N/A
- CRDF N/A
- Revenue Growth
- ZTEK 92.38
- CRDF N/A
- 52 Week Low
- ZTEK $0.50
- CRDF $2.01
- 52 Week High
- ZTEK $1.84
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ZTEK 36.79
- CRDF 41.74
- Support Level
- ZTEK $1.39
- CRDF $2.98
- Resistance Level
- ZTEK $1.55
- CRDF $3.99
- Average True Range (ATR)
- ZTEK 0.09
- CRDF 0.29
- MACD
- ZTEK -0.02
- CRDF -0.08
- Stochastic Oscillator
- ZTEK 2.04
- CRDF 5.34
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.